13 16 hours ago Biotech Stocks Blue Chip Stocks Healthcare Stocks Life Sciences Why CSL’s US$11.7bn Bet On Vifor Has Failed, And If There Is Hope For The Future? It is hard to look back on something and say it failed especially if it was a US$11.7bn bet as CSL's Vifor acquisition was. But what else can you say?… ByNick Sundich